Business Wire

NY-SNOWPLUS

4.6.2021 01:02:05 CEST | Business Wire | Press release

Share
Snowplus Experiences Global Growth Despite COVID

Snowplus , a leading global vape company, and its global business have flourished despite challenges posed by the COVID pandemic that has impacted business around the world. Their strategy of localization implemented in late 2019 has proven to be the key to their continual growth in the face of the pandemic. Since the pandemic started they have still seen a growth increase of around 350% in their global business.

Business impacts of the pandemic have been far reaching, including but not limited to logistics, manufacturing, and local economies being shut down. For the vape industry, it has been no different. However, localized strategies have enabled responsive and agile decision making, and have also minimized any negative impact from the current unforeseen global crisis.

Local Partners

In multiple new markets Snowplus has expanded to, they’ve been able to partner with leading companies that know their local markets well. To win the confidence of top level partners, a combination of quality products, reliable support, and long term investment have proven to be the key.

“Our focus on producing consistently high quality, rigorously tested products have helped us win major partnerships in markets we expand to,” explained Derek Li, Snowplus Cofounder and Head of Overseas Markets. “It’s always a satisfying moment when potential partners test our products, have a ‘wow’ moment, and come back to us ready to work something out.”

Local Strategies

In Canada, Snowplus realized quickly that finding a respected local e-liquid partner would bring down costs associated with e-liquid production and international shipping. But even more importantly, the Canadian palate was quite different from the flavors that make Snowplus pods a hit in Asia. Instead of hoping to have the market warm up to different taste profiles, tailoring flavors that fit local vapers has netted immediate market growth.

In fact, Canada is not the only market where Snowplus implements this two-pronged strategy of establishing local partners and executing local strategies. As a result, not only is Snowplus one of the fastest growing vape brands in the world according to device shipments since they started in 2019, they’ve achieved record growth during the pandemic.

“From our 28-point testing, the most thorough in the industry, to our high-tech laboratories in Shenzhen, our dogged dedication to product quality has opened doors for us in new markets and won over market leading partners wherever we go,” said Li. “In turn, it's been relatively easy for us to work with our local partners and trust their strategies, which has really carried us through this past year of difficulty. In the end, to still achieve record growth has been something we’re extremely proud of and grateful for. We’re not done. As the world slowly emerges from the pandemic, we’re open to any partners that are ready to work with us. Just reach out.”

ABOUT SNOWPLUS

Founded in April 2019, Snowplus is dedicated to replacing combustible tobacco through consistent quality and a commitment to innovating better vaping experiences. Snowplus products have passed a number of third-party safety certifications and are made with components that meet the highest medical safety standards. To date, Snowplus has received over $150 million in financing which is among the largest funding for any startup in the e-cigarette industry.

To learn more about Snowplus, please go to snowplustech.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye